$EVMN

Pena Luis C. sold $382K of EVMN

Pena Luis C. (President & CEO) sold 16,787 shares of Evommune, Inc. (EVMN) at $22.74 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pena Luis C.
Published Jun 4, 2026, 12:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EVMN
Neutral
medium confidence
Mentioned
$EVMN
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVMNNeutralLow
01

Why it matters

This disclosure provides a datapoint on insider behavior but does not, by itself, confirm new company fundamentals; the presence of a 10b5-1 plan typically lowers interpretive weight.

02

Market read

Insider selling may cause short-lived sentiment drift, but traders should treat it as low-signal given the pre-arranged nature of the sale.

03

What to watch

Traders should check whether there are concurrent insider buys/sales or subsequent filings that could clarify whether this is part of a broader pattern.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed June 3 for a sale executed June 1

Background

The article summarizes an SEC Form 4 insider transaction for Evommune, Inc. (EVMN) by its President & CEO, including trade size, price, and post-sale holdings.

Company-level read

Ticker impact

$EVMNNeutralMedium confidence
Context

Evommune CEO sold 16,787 shares in an open-market transaction under a pre-arranged 10b5-1 plan, reducing insider exposure.

Expected impact

Likely limited near-term impact; any reaction should fade unless accompanied by other fundamentals.

Evidence & confidence

The filing is a routine 10b5-1 sale with no accompanying operational or financial catalyst in the article.

Market effects

Minimal; this is company-specific insider activity with no sector-wide disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • Evommune, Inc.

    Subject of the insider transaction disclosure (SEC Form 4) involving its President & CEO.

  • Pena Luis C.

    President & CEO who sold shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Related articles

$EVMNMed

Evommune, Inc. (EVMN): Results of Operations and Financial Condition

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial